Paris, France, October 22, 2019, 7.30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, to... read more

Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia Oslo, Norway, 18 October 2019 Reference is made to the stock exchange release from Nordic Nanovector ASA (OSE: NANO) ("Nordic Nanovector" or the "Company"... read more

DUBLIN, Ireland and TREVOSE, Pa., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that ... read more

Oslo, Norway, 9 October 2019 Nordic Nanovector ASA (OSE: NANO) announces that the Company and its collaborators at Orano Med will present data and analyses from preclinical studies with 212Pb-NNV003, a CD37 targeting alpha-radioimmunotherapy for the treatment of leukaemia and lymphoma at t... read more

First study to find direct evidence that therapeutic gene is transferred from the injected eye to the uninjected contralateral eye of primates Findings support mechanism for bilateral visual improvement with unilateral GS010 gene therapy, which was consistently observed in LHON subjects in th... read more